Feasibility of MASK-air® use in allergic rhinitis patients receiving immunotherapy and the effect on quality of life
Main Article Content
Keywords
allergic rhinitis, immunotherapy, MASK-air®, quality of life
Abstract
Background: The aim of MASK-air® application is to enhance awareness of allergic rhinitis (AR) and its complications, thereby reducing the risk of developing asthma.
Objective: The aims of this study were to evaluate the impact of MASK-air® on the quality of life (QoL) and symptomatology of AR patients undergoing allergen immunotherapy (AIT). The study also evaluated patient satisfaction with the application.
Materials and Methods: A prospective cross-sectional study was conducted between August and November 2019 at a tertiary Allergy and Immunology center involving patients receiving AIT. Participants were instructed on accessing and utilizing MASK-air® daily through face-to-face interviews. Concurrently, the Score for Allergic Rhinitis (SFAR) and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) were administered alongside MASK-air® Visual Analog Scale (VAS) scores. After 6 months, RQLQ scores were reassessed and a satisfaction survey was conducted.
Results: This study comprised 96 patients. Significant correlations were observed among SFAR, RQLQ, and VAS scores. After 6 months of MASK-air® usage, improvements in QoL and symptom reduction were evident. Notably, participants who consistently used MASK-air® demonstrated significant reductions in activity limitations and hay fever scores compared to irregular users (p = 0.05 and p = 0.02, respectively). Additionally, participants under 40 years of age and those with higher education levels exhibited a greater inclination toward online monitoring via the application. Overall, participants found MASK-air® practical, citing various advantages and disadvantages.
Conclusion: MASK-air® serves as a valuable tool for physicians in managing treatment and is associated with validated, reliable scales. Its use was linked to enhanced QoL and symptom reduction among participants, irrespective of treatment duration.
References
2 Mims JW. Epidemiology of allergic rhinitis. Int Forum Allergy Rhinol 2014;4(Suppl 2):18–20. 10.1002/alr.21385
3 Kurt E, Metintas S, Basyigit I, Bulut I, Coskun E, Dabak S, et al. Prevalence and risk factors of allergies in Turkey (PARFAIT): Results of a multicentre cross-sectional study in adults. Eur Respir J 2009;33(4):724–33. 10.1183/09031936.00082207
4 Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: A critical evaluation of the literature. Pharmacoeconomics 2004;22(6):345–61. 10.2165/00019053-200422060-00002
5 Cingi C, Songu M, Ural A, Annesi-Maesano I, Erdogmus N, Bal C, et al. The score for allergic rhinitis study in Turkey. Am J Rhinol Allergy 2011;25(5):333–7. 10.2500/ajra.2011.25.3665
6 Zuberbier T, Bachert C, Bousquet PJ, Passalacqua G, Walter Canonica G, Merk H, et al. GA2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010;65(12):1525–30. 10.1111/j.1398-9995.2010.02474.x
7 Penagos M, Durham SR. Allergen immunotherapy for long-term tolerance and prevention. J Allergy Clin Immunol 2022;149(3):802–11. 10.1016/j.jaci.2022.01.007
8 Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Allergic rhinitis and its impact on asthma (ARIA): Achievements in 10 years and future needs. J Allergy Clin Immunol 2012;130(5):1049–62. 10.1016/j.jaci.2012.07.053
9 Yorgancıoğlu AA, Kalayci Ö, Cingi C, Gemicioğlu B, Kalyoncu AF, Agache I, et al. ARIA 2016 executive summary: Integrated care pathways for predictive medicine across the life cycle. Tuberk Toraks 2017;65(1):32–40. 10.5578/tt.52766
10 Yorgancıoğlu AA, Gemicioğlu B, Kalaycı Ö, Kalyoncu AF, Cingi C, Murray R, et al. Türkiye’de mask (Mobile Airways Sentinel networK) allerji günlüğü uygulaması: Allerjik rinit ve astımda arıa ile bütünleşmiş mobil teknoloji kullanımı. Tuberk Toraks 2018;66(2):176–81. 10.5578/tt.66913
11 Cuesta-Herranz J, Laguna JJ, Mielgo R, Pérez-Camo I, Callejo AM, Begoña L, et al. Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA). Eur Ann Allergy Clin Immunol 2019;51(5):10.23822/EurAnnACI.1764-1489.104. 10.23822/EurAnnACI.1764-1489.104
12 Morris MS, Lowery A, Theodoropoulos DS, Duquette RD, Morris DL. Quality of life improvement with sublingual immunotherapy: A prospective study of efficacy. J Allergy (Cairao) 2012;2012:1–6. 10.1155/2012/253879
13 Yalcin AD, Öncel S, Akcan A, Eravsar K, Polat HH, Terzioglu E. Antalya’da 16 yaş üstünde allerjik astim, rinit ve konjonktivit prevalansi. Turkiye Klin J Med Sci 2010;30(3):888–94. 10.5336/medsci.2008-9901
14 Fröhlich M, Pinart M, Keller T, Reich A, Cabieses B, Hohmann C, et al. Is there a sex-shift in prevalence of allergic rhinitis and comorbid asthma from childhood to adulthood? A meta-analysis. Clin Transl Allergy 2017;7:44. Published 2017 Dec 5. 10.1186/s13601-017-0176-5
15 Zhang Y, Lan F, Zhang L. Advances and highlights in allergic rhinitis. Allergy 2021;76(11):3383–9. 10.1111/all.15044
16 Bousquet PJ, Cropet C, Klossek JM, Allaf B, Neukirch F, Bousquet J. Effect of smoking on symptoms of allergic rhinitis. Ann Allergy Asthma Immunol 2009;103(3):195–200. 10.1016/S1081-1206(10)60181-0
17 Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, et al. EAACI guidelines on allergen immunotherapy: Allergic rhinoconjunctivitis. Allergy 2018;73(4):765–98. 10.1111/all.13317
18 Sakar A, Yorgancioglu A, Dinc G, Yuksel H, Celik P, Dagyildizi L, et al. The prevalence of asthma and allergic symptoms in Manisa, Turkey (a western city from a country bridging Asia and Europe). Asian Pacific J Allergy Immunol 2006;24(1):17–25.
19 Başak O, Başak S, Gültekin B, Tekin N, Söylemez A. The prevalence of allergic rhinitis in adults in Aydin, Turkey. Rhinology 2006;44(4):283–7.
20 Öztürk Ö, Tokmak A, Güçlü E. Skin prick test results of patients with allergic rhinitis in Düzce. Duzce Med J 2005;7(1):11–4.
21 Edıger D, Günaydin FE, Erbay M, Şeker Ü. Trends of sensitization to aeroallergens in patients with allergic rhinitis and asthma in the city of Bursa, south Marmara sea region of Turkey. Turkish J Med Sci 2020;50(2):330–6. Published 2020 Apr 9. 10.3906/sag-1908-139
22 Specjalski K, Łata J, Wasilewska E, Chełmińska M, Jassem E, Niedoszytko M, et al. Smoking history is negatively associated with allergen specific immunotherapy efficacy: A retrospective analysis. Postep Dermatologii i Alergol 2019;36(6):673–6. 10.5114/ada.2018.80654
23 Vieira RJ, Sousa-Pinto B, Cardoso-Fernandes A, Jácome C, Portela D, Amaral R, et al. Control of allergic rhinitis and asthma test: A systematic review of measurement properties and COSMIN analysis. Clin Transl Allergy 2022;12(9):e12194. 10.1002/clt2.12194
24 Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol 2017;140(4):950–8. 10.1016/j.jaci.2017.03.050
25 Bousquet J, Arnavielhe S, Bedbrook A, Bewick M, Laune D, Mathieu-Dupas E, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy 2018;8:45. Published 2018 Oct 25. 10.1186/s13601-018-0227-6
26 Spinozzi F, Murgia N, Baldacci S, Maio S, Pala AP, Casciari C, et al. Characteristics and predictors of allergic rhinitis undertreatment in primary care. Int J Immunopathol Pharmacol 2016;29(1):129–36. 10.1177/0394632015595779
27 Bédard A, Antó JM, Fonseca JA, Arnavielhe S, Bachert C, Bedbrook A, et al. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App. Allergy 2020;75(7):1672–88. 10.1111/all.14204
28 Pedregal-Mallo D, Pacheco E, Rodrigo JP, Llorente JL, Alvarez-Marcos C. Impact of immunotherapy on quality of life in patients with house dust mite allergic rhinitis. Allergy. 2020;75(7):1783–5. 10.1111/all.14215
29 Schwanke T, Carragee E, Bremberg M, Reisacher WR. Quality-of-life outcomes in patients who underwent subcutaneous immunotherapy and sublingual immunotherapy in a real-world clinical setting. Am J Rhinol Allergy 2017;31(5):310–6. 10.2500/ajra.2017.31.4465
30 Menditto E, Guerriero F, Orlando V, Crola C, Di Somma C, Illario M, et al. Self-assessment of adherence to medication: A case study in campania region community-dwelling population. J Aging Res 2015;2015:682503. 10.1155/2015/682503
